This is a paid press release. Contact the press release distributor directly with any enquiries.
MediPharm Labs Sets Date to Report Third <a href="https://bitcomme.com/is-there-a-risk-hiding-in-salesforce-stocks-record-quarter/” title=”Is There A Risk Hiding In Salesforce Stock’s Record Quarter?”>Quarter 2026 Financial Results
- LABS.TO
- MLZ.F
- MEDIF
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, will release its third quarter financial results for the three and nine months ended September 30th, 2026, before markets open on Thursday, November 12th, 2026.
MediPharm Labs executive management team will also host a conference call and webcast on November 12th, 2026, at 10:00 a.m. (Eastern time) to discuss the Company’s financial results.
Conference Call Dial in Details:
United States Toll-Free: (833) 461-5787
Canada Toll-Free: (833) 769-6440
International: dial-in numbers are available here.
Meeting ID: 571066887
Participants are asked to dial in approximately 15 minutes before the start of the call.
Webcast:
A webcast will be available by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company’s current foreign drug manufacturing site registration with the US FDA. MediPharm Labs also has EUGMP certification, ANVISA GMP certification from Brazil and TGA compliance in Australia.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm Labs’ reach to medical patients in Canadad Germany through Beacon Medical PTY and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions
